Steven Nathan, MD
Pulmonary Disease · Falls Church, VANPI 1891724134
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (49.8%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 53 manufacturers reported payments, led by Boehringer Ingelheim at 44.7% of the total. Among pulmonary disease clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,358 payments — averaging $1079.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$655K
- United Therapeutics Corporation$402K
- Genentech USA, Inc.$114K
- F. Hoffmann-la Roche AG$71K
- Merck$33K
- Boehringer Ingelheim International GmbH$33K
- plus $158K from 47 others
Across 197 payments — averaging $5896.77 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- United Therapeutics Corporation$685K
- Rigel Pharmaceuticals, Inc.$229K
- Biogen$163K
- F. Hoffmann-la Roche AG$44K
- AbbVie$17K
- Genentech, Inc.$14K
- plus $8K from 1 others
What the payments were for
- Consulting fees$550,40238%
- Speaking & faculty fees$730,57750%
- Travel & lodging$157,55811%
- Food & beverage$27,2092%
- Education$1180%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OFEV$439,317
- Esbriet$197,848
- TYVASO$193,350
- Adempas$18,978
- REMODULIN$9,177
- ORENITRAM$5,719
- MK-5475$5,650
- NONE$4,275
- Enhertu$4,143
- Non-Covered Product$2,580
- UPTRAVI$2,480
- OPSUMIT$2,480
- XOLAIR$2,240
- GLASSIA$1,980
- WINREVAIR$1,020
- KEYTRUDA$375
- FLOWTRIEVER CATHETER, S$357
- CT THROMBECTOMY SYSTEM KIT$357
- NUCALA$124
- LIVTENCITY$120
How this compares
$1,465,864 in reported general payments places this provider in the 95th percentile of 317 pulmonary disease providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 199 | $2,631,372 |
| Tyvaso DpiTreprostinil | 37 | $851,060 |
| OpsumitMacitentan | 35 | $424,245 |
| Pirfenidone | 45 | $178,554 |
| AdempasRiociguat | 12 | $169,323 |
| LetairisAmbrisentan | 12 | $158,626 |
| GlassiaAlpha-1-Proteinase Inhibitor | 11 | $53,238 |
| Tadalafil | 15 | $43,091 |
| EliquisApixaban | 11 | $6,430 |
| Spiriva HandihalerTiotropium Bromide | 11 | $5,539 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $4,404 |
| Mycophenolate Mofetil | 20 | $1,949 |
| Midodrine Hcl | 13 | $1,751 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 26 | $318 |
| Prednisone | 64 | $315 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev | $655,431 | $2,631,372199 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit | $2,755 | $424,24535 claims |
| BayerAdempas | $19,909 | $169,32312 claims |
| GileadLetairis | $287 | $158,62612 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Glassia | $2,319 | $53,23811 claims |
| GSKBreo Ellipta | $124 | $4,40411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 317 pulmonary disease providers in Virginia.
Other pulmonary disease in Falls Church
- Rabih HalabiFalls Church$604K
- Vikramjit KhangooraFalls Church$49K
- Shambhu AryalFalls Church$48K
- Anne BrownFalls Church$31K
- Omar MinaiHopewell$1.3M
- Eric LibreAnnandale$302K
- Sujoy GillRichmond$296K
- Imre NothCharlottesville$256K
- Carlos SilvaChesapeake$245K
- Vijay SubramaniamWilliamsburg$228K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.